Current Report Filing (8-k)
November 06 2020 - 05:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6,
2020
BioSig Technologies,
Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
001-38659
|
26-4333375
|
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer
|
of incorporation)
|
|
Identification No.)
|
54 Wilton Road, 2nd Floor
Westport,
Connecticut
|
|
06880
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(203)
409-5444
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
BSGM
|
|
The NASDAQ Capital
Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
7.01 Regulation
FD Disclosure.
BioSig Technologies, Inc. (the “Company”) intends,
from time to time, to present and/or distribute to the investment
community and utilize at various industry and other conferences a
slide presentation, which is attached hereto as Exhibit 99.1. The
Company undertakes no obligation to update, supplement or amend the
materials attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Exchange Act or
the Securities Act of 1933, as amended, except as shall be
expressly set forth by reference in such a filing. Furthermore, the
furnishing of information under Item 7.01 of this Current Report on
Form 8-K is not intended to constitute a determination by the
Company that the information contained herein, including the
exhibits hereto, is material or that the dissemination of such
information is required by Regulation FD.
Item
9.01 Financial
Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
BIOSIG TECHNOLOGIES, INC.
|
|
|
|
|
Date: November 6, 2020
|
By: /s/ Kenneth L.
Londoner
Name: Kenneth L. Londoner
Title: Executive Chairman
|
|
|
NASDAQ false 0001530766
0001530766 2020-11-06 2020-11-06